PA-PROJECT-MANAGEMENT
21.10.2020 15:02:12 CEST | Business Wire | Press release
Project Management Institute (PMI), the world’s leading association for the project management profession, today launched the industry’s first, platform-agnostic educational resources for organizations seeking to implement and scale Citizen Development (CD) practices. The first two products in a planned suite of offerings are available now:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201021005531/en/
- The PMI Citizen Development Body of Knowledge (CDBOK™) is a centralized resource that will help individuals and enterprises understand best practices for implementing citizen development within an organization at scale.
- The foundational training course is an e-learning training program that provides an introduction to citizen development and outlines best practices in CD methodologies.
Citizen development platforms use intuitive “low-code” and “no-code” tools, so that even non-technical, non-specialist employees can create apps, software solutions and even enterprise-grade applications without having to learn to code. The emergence of citizen development promises to improve enterprise productivity by making application and software development significantly faster and less costly, while also accelerating value delivery and enabling organizations to achieve outcomes more quickly.
“PMI is ideally positioned to help drive adoption of citizen development,” says Sunil Prashara, PMI President and CEO. “As the world’s leading not-for-profit association for the project management profession, we’ve spent the past 50 years equipping our stakeholders with the most relevant skills and resources so they can deliver change and business value, all to help their organizations succeed. To ensure we are providing the right tools for citizen development, we have tapped leading experts in the field and combined their knowledge and expertise with our own deep experience developing global standards and certification training for project managers all around the world. With more than 600,000 members and 1.5 million gross credential holders in nearly every country, we can serve as an objective resource for organizations and individuals looking to apply citizen development tools and methodologies thoughtfully and with confidence.”
Citizen Development Helps Pave the Way for the Next Wave of Business Transformation
Citizen development should ease the burden on over-taxed IT departments straining to cope with growing demands for support from business units. Forrester Research estimates that by 2024 the U.S. will have a deficit of 500,000 software developers.
“Citizen development will form the next wave of business transformation,” says Mr. Prashara. “Technological advances such as AI are eliminating much of the complexity involved in software development, allowing non-specialists to create their own solutions and bring new products and services to market in unprecedented timeframes. This will democratize software development and turbocharge digital transformation efforts.”
Citizen development enables a “hyper-agile” way of working, which can lead to substantial reductions in cost and development times. With citizen development, the speed at which you can take an idea and design, build, test and deploy apps enables teams and organizations to deliver projects and bring products and services to market faster than ever before.
Scaling Citizen Development at the Enterprise Level, Safely and Securely with PMI
Gartner estimates that the number of active citizen developers will be four times that of professional developers by 2023. PMI’s new suite of products should help facilitate that transition, allowing organizations to promote citizen development among their employees in a measured and secure way.
According to Gartner, 41 percent of business leaders report having active citizen development initiatives underway, with 20 percent either evaluating or planning to start CD initiatives. However, to derive maximum benefit from citizen development, organizations will need to scale it across the enterprise, creating an organizational operating system. There is an urgent need to enable this level of scalability in order to drive transformation efforts, Mr. Prashara says, and that was the driving force behind developing the new PMI offerings.
“PMI recognizes the critical role that citizen development plays in empowering individuals and organizations,” Mr. Prashara says. “As organizations look to leverage citizen development in their digital transformation programs, there are many pitfalls to avoid, including the lack of a comprehensive methodology and framework and adequate training to allow citizen developers to succeed. PMI is addressing this gap by providing a vendor-agnostic framework to support professionals’ need to learn the basics and best practices, but also organizations’ need to unlock the potential of citizen development in compliance with IT governance and security. This will give IT the confidence to scale citizen development across the enterprise to accelerate the organization’s transformation efforts.”
PMI Citizen Developer Products & Experiences in the Pipeline
While the initial offerings are available now, PMI will launch additional PMI Citizen Developer products in the coming months, to include specific role-based courses and certifications, as well as a community portal for sharing CD information and thought leadership. The PMI Citizen Development Body of Knowledge (CDBOK™) will also be followed by an executive book on CD best practices, highlighting specific case studies and leadership perspectives.
To learn how to unlock the potential of citizen development at your organization, go to: pmi.org/citizen-developer .
About Project Management Institute (PMI)
Project Management Institute (PMI) is the world's leading association for those who consider project, program or portfolio management their profession. Through global advocacy, collaboration, education and research, we work to prepare more than three million professionals around the world for The Project Economy: the coming economy in which work, and individuals, are organized around projects, products, programs and value streams. Now 50 years in the making, we work in nearly every country around the world to advance careers, improve organizational success and further mature the project management profession through globally-recognized standards, certifications, communities, resources, tools, academic research, publications, professional development courses and networking opportunities. As part of the PMI family, ProjectManagement.com® interactive website creates online global communities that deliver more resources, better tools, larger networks and broader perspectives. Visit us at www.PMI.org , www.projectmanagement.com , www.facebook.com/PMInstitute and on Twitter @PMInstitute.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201021005531/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom